Physician profile
Nicholas Rock
NPI 1619525383
$3,579.75
in general payments reported to CMS, 2019-2025
19 companies · $719 in 2025
The $719 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $516 · 2023: $883 · 2024: $945 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,440.84 |
| Education | $106.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.16 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $466.06 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.02 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $330.53 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Indivior INC. | $279.01 | 2022-2025 | Sublocade, Perseris |
| Alkermes, INC. | $213.32 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $195.18 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $181.67 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Gilead Sciences, INC. | $121.18 | 2024 | Epclusa |
| Bioxcel Therapeutics, INC. | $112.43 | 2023 | Igalmi |
| Neurocrine Biosciences, INC. | $109.76 | 2021 | |
| Lundbeck LLC | $91.59 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $50.70 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $47.96 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $37.82 | 2022-2025 | Xelstrym, Secuado |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $33.44 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $28.90 | 2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $28.12 | 2022 | |
| Calliditas Therapeutics US INC. | $14.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Rock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.